Detection antibody for neuronal intranuclear inclusion disease and detection method using the same

An antibody targeting the NOTCH2NLC gene's GGC repeat sequence polypeptide allows for precise NIID diagnosis through immunohistochemistry, overcoming diagnostic challenges and ethical concerns.

JP2024158581APending Publication Date: 2024-11-08AICHI MEDICAL UNIVERSITY

Patent Information

Application Number
JP2023073892
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing methods for diagnosing Neuronal Intranuclear Inclusion Disease (NIID) face challenges such as false negatives with hematoxylin and eosin staining, ethical concerns with genetic diagnosis, and difficulties in detecting NIID in cases with primer hybridization mutations, necessitating a more accurate and ethical testing method.

Method used

Development of an antibody that specifically binds to a polypeptide containing the amino acid sequence of SEQ ID NO: 1, derived from the NOTCH2NLC gene's GGC repeat sequence, for detecting intranuclear inclusion bodies through immunohistochemical staining.

Benefits of technology

The antibody enables accurate and ethical diagnosis of NIID by identifying abnormal proteins in cell nuclei, distinguishing it from similar conditions like FXTAS, without requiring genetic testing, and is applicable to skin biopsies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158581000002
    Figure 2024158581000002
  • Figure 2024158581000003
    Figure 2024158581000003
  • Figure 2024158581000004
    Figure 2024158581000004
Patent Text Reader

Abstract

To provide a testing method capable of accurately and simply diagnosing neuronal intranuclear inclusion disease.SOLUTION: The inventors have discovered that the causative gene of neuronal intranuclear inclusion disease is an extension of the GGC repeat sequence in the NOTCH2 NLC gene and developed an antibody specifically binding to the abnormal protein expressed due to this expansion. This invention provides the antibody, a method for detecting intranuclear inclusions in the neuronal intranuclear inclusion disease using the antibody, and a diagnostic agent and kit for the neuronal intranuclear inclusion disease using the antibody.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antibody for detecting neuronal intranuclear inclusion disease and a detection method using the same. [Background technology]

[0002] Neuronal Intranuclear Inclusion Disease (also known as NIID) is a progressive neurological disorder characterized by dementia, functional impairment, and muscle weakness in the limbs. It is an incurable disease in which foreign bodies called "inclusion bodies" are found in the "cell nuclei" of cells in nervous tissue such as the cerebrum, spinal cord, and peripheral nerves, and in cells of general organs. "Inclusion bodies" are deposits formed by the accumulation of proteins and other substances, but their details are unknown.

[0003] Although NIID shares common pathological characteristics such as "loss of nerve cells," it does not necessarily involve significant nerve cell loss, and the location and degree of nerve cell loss varies from case to case. Therefore, due to the diversity of main clinical symptoms, premortem diagnosis was difficult.

[0004] In 2011, the present inventors reported that NIID can be diagnosed from skin biopsy tissue (see Non-Patent Document 1). In this study, neuronal intranuclear inclusions were stained eosinophilically when hematoxylin-eosin staining was performed on skin biopsy samples, or were stained positively by anti-ubiquitin or anti-p62 antibodies when immunofluorescence staining was performed using anti-ubiquitin or anti-p62 antibodies.

[0005] In 2019, the inventors performed genome analysis using many family cases diagnosed by skin biopsy and identified that the causative gene of NIID is an extension of the GGC repeat sequence present in the 5' untranslated region of the NOTCH2NLC gene (Notch 2 N-terminal like C) (see Non-Patent Documents 2 and 3). A method for detecting NIID patients focusing on the GGC repeat sequence of the NOTCH2NLC gene has also been developed (see, for example, Patent Document 1). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent Publication No. 2021-108552 [Non-patent literature]

[0007] [Non-Patent Document 1] Sone J, et al., “Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease”, Neurology 2011;76:1372-1376 [Non-Patent Document 2] Sone J, et al., “Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease”, Nature Genetics, 2019;51:1215-1221 [Non-Patent Document 3] Sone J, et al., “Long-read sequencing identifies GGC repeat expansion in human-specific NOTCH2NLC associated with neuronal intranuclear inclusion disease”, Biorxiv, 2019 Summary of the Invention [Problem to be solved by the invention]

[0008] After the inventors reported in 2011 that skin biopsy was effective for diagnosing NIID, the number of NIID cases increased dramatically. However, hematoxylin-eosin staining alone still sometimes gave false negative results.

[0009] In addition, NIID was strongly suspected in head MRI imaging diagnosis, clinical diagnosis such as symptoms, and when skin samples were stained with anti-p62 antibodies, but it has been reported that intranuclear inclusions similar to those in NIID were also found in the skin of patients with FXTAS (Fragile X-associated tremor / ataxia syndrome), which exhibits pathological images similar to those of NIID. Therefore, a test method that can distinguish between NIID and FXTAS when NIID is strongly suspected in clinical diagnosis or skin biopsy has been required.

[0010] Although genetic diagnosis has become possible by identifying the causative gene of NIID, genetic diagnosis entails ethical issues, as it may reveal genetic abnormalities or diseases in family members or blood relatives. Therefore, a method that can accurately diagnose NIID without genetic diagnosis was needed.

[0011] Patent Document 1 describes a method for detecting NIID that focuses on the GGC repeat sequence of the NOTCH2NLC gene. However, because this is a technique that uses PCR, in cases where there is a mutation in the part where the primer hybridizes, the PCR reaction may not occur correctly, and the extension of the repeat sequence may not be detected.

[0012] Therefore, there is a need for a test method that can diagnose NIID easily and accurately. [Means for solving the problem]

[0013] The inventors have focused on the fact that the causative gene of NIID is an extension of the GGC repeat sequence on the NOTCH2NLC gene, and have found that the extension of the GGC repeat sequence contributes to the expression of an abnormal protein. The inventors have speculated that NIID is caused by the deposition of aggregates of this abnormal protein in the cell nucleus. Therefore, the inventors have created an antibody that specifically binds to the protein, developed a method for detecting intranuclear inclusions in NIID using the antibody, and developed a diagnostic agent and a diagnostic kit for NIID using the antibody, and have completed the present invention. That is, the present invention has been made to solve the above-mentioned problems, and the embodiments of the present invention may include the following configurations. (1) An antibody that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1. (2) A method for detecting intranuclear inclusions in neuronal intranuclear inclusion disease, comprising the following steps: (A) contacting a biological sample with the antibody described in (1). (B) detecting the intranuclear inclusions bound to the antibody by immunohistochemical staining. (3) A diagnostic agent for neuronal intranuclear inclusion disease, comprising the antibody according to (1). (4) A kit for diagnosing neuronal intranuclear inclusions, comprising the antibody according to (1) and a detection reagent for detecting the antibody. Effect of the Invention

[0014] The antibody of the present invention specifically binds to an abnormal protein expressed by the extension of the GGC repeat sequence on the NOTCH2NLC gene, which is the causative gene for NIID. Since NIID is a disease in which abnormal structures in which proteins and the like are accumulated, called "inclusion bodies," are found in the cell nucleus, an antibody that binds to such proteins can be used to accurately detect intranuclear inclusion bodies in NIID, and diagnostic agents and diagnostic kits using such antibodies can accurately diagnose NIID. In particular, the diagnosis can be made by skin biopsy, making the test easy and convenient. In addition, since no genetic diagnosis is performed, there are no ethical issues inherent in genetic diagnosis. [Brief description of the drawings]

[0015] [Figure 1] An example of the NOTCH2NLC repeat consensus sequence. [Diagram 2] RNA sequencing analysis of the NOTCH2NLC gene in fibroblasts from two NIID patients (F1-16 and F1-14) and two non-NIID patients (F1-7 and F1-18). Reads derived from the sense and antisense strands of NOTCH2NLC. Forward (F) and reverse (R) strand sequences are shown (left panel). IGV image of NOTCH2NLC-AS reads near the GGC repeat (right panel). [Diagram 3] Immunofluorescence staining of dorsal root ganglion neurons (NIID case). (a) DAPI stained image, (b) anti-p62 antibody stained image, (c) S1 antibody stained image, (d) differential interference contrast image, (e) a composite image of the above four images. [Figure 4] Immunofluorescence staining of dorsal root ganglion neurons (NIID case). (a) DAPI stained image, (b) anti-p62 antibody stained image, (c) S2 antibody stained image, (d) differential interference contrast image, (e) a composite image of the above four images. [Diagram 5] Immunofluorescence staining of dorsal root ganglion neurons (NIID case). (a) DAPI stained image, (b) anti-p62 antibody stained image, (c) S3 antibody stained image, (d) differential interference contrast image, (e) a composite image of the above four images. [Figure 6]Figure of immunofluorescence staining using pontine neurons (DRPLA case). (a) DAPI staining image, (b) anti-1C2 antibody staining image, (c) S2 antibody staining image, (d) differential interference image, (e) composite image of the above 4 images [Figure 7] Figure of immunofluorescence staining using pontine neurons (SCA3 case). (a) DAPI image, (b) anti-1C2 antibody staining image (c) S2 antibody staining image, (d) differential interference image, (e) composite image of the above 4 images [Figure 8] Figure of immunofluorescence staining using skin fibroblasts (FXTAS case). (a) DAPI image, (b) anti-p62 antibody staining image (c) S2 antibody staining image, (d) differential interference image, (e) composite image of the above 4 images [Figure 9] Figure of immunofluorescence staining using skin fibroblasts (FXTAS case). (a) DAPI image, (b) anti-p62 antibody staining image (c) anti-polyglycine antibody staining image, (d) differential interference image, (e) composite image of the above 4 images [Figure 10] Figure of immunofluorescence staining using skin fibroblasts (NIID case). (a) DAPI image, (b) anti-p62 antibody staining image (c) S2 antibody staining image, (d) differential interference image, (e) composite image of the above 4 images

Mode for Carrying Out the Invention

[0016] Hereinafter, embodiments of the present invention will be described in detail, but the scope of the present invention is not limited to these embodiments. <NIID and Extension of GGC Repeat Sequence on NOTCH2NLC Gene>

[0017] The NOTCH2NLA, NOTCH2NLB, and NOTCH2NLC genes are human-specific genes, and are paralogs of NOTCH2 exons 1 to 5. They code for the Notch 2 N-terminal like (N2L) protein, which controls the Notch signal that expands human neural progenitor cells during brain development. The present inventors reported that the causative gene of NIID is an extension of the GGC repeat sequence present in exon 1 on the NOTCH2NLC gene (see Non-Patent Document 2). Specifically, a linkage map of a large family with multiple affected individuals was created using whole exome sequencing (WES) or Illumina HiSeq whole genome sequencing (WGS) data of seven affected and seven unaffected individuals. Furthermore, analysis using Oxford Nanopore's long-read next-generation sequencer, MinION, became possible, and it was identified that the causative gene of NIID is an extension of the GGC repeat sequence on the NOTCH2NLC gene on chromosome 1 (see FIG. 1).

[0018] Because the GGC repeat sequence is located more than 100 nt upstream of the ATG start codon that initiates the N2C open reading frame (ORF), alteration of NOTCH2NLC (N2C) protein function in NIID is unlikely. Furthermore, because NOTCH2NLC mRNA levels are unchanged in individual patients with NIID, it was unclear how the expansion of GGC repeats embedded in the untranslated region leads to the formation of intranuclear inclusions.

[0019] In addition, since GGC repeat sequences may contain GGA sequences mixed therein, GGC may be expressed as GGN (N is C or A) in this specification.

[0020] Here, we will explain Repeat Associated Non-AUG translation (sometimes referred to as "RAN Translation"). RAN Translation is an irregular translation pattern of mRNA that can occur in eukaryotic cells. The translation of eukaryotic mRNA usually starts at the AUG codon closest to the 5' end of the mRNA capped with 7-methylguanosine. However, it has been discovered that when there is a repeat sequence of a specific base sequence, translation can occur even without a normal AUG start codon. RNA Translation, in which the repeat sequence is translated into a protein that tends to aggregate from multiple reading frames, is thought to play an important role in genetic diseases (especially neurological diseases). There is also a theory that translation initiation other than AUG occurs at "near-cognate" start codons that are one base shorter than AUG, such as CUG and GUG. However, since it is推测 that the surrounding sequence context also has a dramatic impact, the number of repeats, the pattern of the repeat sequence, the start and stop points, and the differences and similarities with the conventional translation mechanism required for RAN Translation to occur are currently unknown.

[0021] <Amino acids translated by the extension of the GGC repeat sequence> Previously, the inventors published data showing that abnormal antisense transcripts were found only in affected samples, starting from or within the extended repeat region, and not in non-affected samples (see Figure 2). From this, the inventors推测 that the GGC repeat sequence induces RAN Translation.

[0022] The amino acids encoded by the GGC repeat sequence include glycine, alanine, proline, and arginine. Or there is a polypeptide consisting of the above amino acid sequence. However, since it does not have an AUG start codon, it is unknown where protein translation starts. The inventors focused on the base sequence continuously present in the 5' direction from the GGC repeat sequence, as there are reports of diseases among repeat diseases where the disease state does not develop only by expressing the amino acids encoded by the repeat sequence, and examined the amino acids encoded thereby.

[0023] As a result, the inventors found that a polypeptide containing the amino acid sequence of SEQ ID NO: 1 is specifically expressed in the nuclear inclusion of NIID, leading to the completion of the present invention. In other words, the antibody of the present invention specifically recognizes a polypeptide containing the amino acid sequence of SEQ ID NO: 1. The amino acid sequence of SEQ ID NO: 1 is a sequence of 18 consecutive amino acids as shown below. This serves as an immunizing antigen.

[0024] Arg Leu Gly Arg Ser Thr Trp Gly Gly Gly Pro Asp Arg Gly Ala Pro Leu Ser

[0025] The polypeptide is not limited to any other amino acid sequence as long as it contains the amino acid sequence of SEQ ID NO: 1. For example, cysteine ​​may be inserted at the N-terminus or C-terminus of the peptide in order to bind a carrier described below via SH.

[0026] Here, carriers will be explained. Peptides of 8 to 30 amino acid residues may not have immunogenicity because of their small molecular weight. In this case, they can be used as immunogens by binding to a carrier or by preparing a Multiple Antigen Peptide (MAP) peptide using the MAP method.

[0027] When binding to a carrier, the carrier is bound via an SH group, so cysteine ​​may be inserted into the N-terminus or C-terminus of the peptide. It is preferably inserted into the N-terminus. Examples of the carrier include carrier proteins and polymers. Examples of the carrier protein include bovine serum albumin, keyhole limpet hemocyanin (KLH), heterologous proteins such as thyroglobulin and ovalbumin. Examples of the polymer include sugars such as mannan or chitosan, and polyvinylpyrrolidone (PVA).

[0028] The polypeptide of the present invention may be appropriately modified, such as with biotin, a fluorescent dye, a sugar chain, or a lipid. The site of such modification is not particularly limited, and may be any of the inside of the peptide, the C-terminus of the peptide, or the N-terminus of the peptide.

[0029] The origin of the polypeptide in the present invention is not particularly limited, and may be, for example, a peptide derived from tissues or cells of a human or non-human mammal, or may be a synthetic peptide. Examples of non-human mammals include mice, rats, hamsters, guinea pigs, rabbits, chickens, and dogs.

[0030] The polypeptide of the present invention can be synthesized by a known method. A chemical synthesis method using a peptide synthesizer or the like may be adopted, and a biochemical synthesis method may be adopted, and is not limited to either method. Examples of chemical synthesis methods for peptides include solid-phase synthesis methods such as the Fmoc method and the tBOC method, and liquid-phase synthesis methods. Examples of biochemical synthesis methods for peptides include a method in which a nucleic acid having a base sequence encoding the amino acid sequence of a peptide is introduced into a host cell (e.g., a mammalian cell, an insect cell, E. coli, etc.), the peptide is expressed in the host cell, and the peptide is extracted and purified to obtain the peptide. The peptide obtained by synthesis can be isolated and purified by a known purification method, such as extraction, precipitation, electrophoresis, chromatography, etc. If the peptide obtained by the above method is in a free form, it can be converted into an appropriate salt by a known method, and if it is obtained as a salt, it can be converted into a free form by a known method.

[0031] <Antibody and its manufacturing method> The antibody of the present invention specifically recognizes and binds to a polypeptide containing the amino acid sequence of SEQ ID NO: 1. By using such an antibody, abnormal proteins containing GGC repeat sequences in biological samples can be detected.

[0032] Here, the biological sample is not particularly limited as long as it is collected from a human and is expected to contain nucleic acids and proteins derived from the GGC repeat sequence of the NOTCH2NLC gene. It can be easily prepared by a conventional method from biopsy or surgically removed samples of various organs, autopsy samples, peripheral blood, oral mucosa swabs, etc.

[0033] The antibody of the present invention may be a polyclonal antibody, a monoclonal antibody, or a recombinant antibody obtained by recombinant genetic engineering technology, so long as it specifically recognizes and binds to a polypeptide containing the amino acid sequence of SEQ ID NO: 1 of the present invention. From the viewpoint of ease of production, a polyclonal antibody is preferable. Furthermore, the antibody of the present invention may be any of the isotypes IgG, IgM, IgA, IgD, and IgE.

[0034] The antibodies of the present invention (eg, polyclonal or monoclonal antibodies) can be produced by well-known methods.

[0035] For example, a polyclonal antibody can be produced by immunizing a mammal with a polypeptide (immunizing antigen) containing the amino acid sequence of SEQ ID NO: 1 of the present invention, collecting blood from the mammal, and isolating and purifying the antibody from the collected blood. The mammals used are preferably mice, rats, hamsters, guinea pigs, rabbits, chickens, dogs, goats, sheep, and cows. Methods of antigen administration are known to those skilled in the art, and the administration route is not particularly limited. Subcutaneous administration, intradermal administration, intraperitoneal administration, intravenous administration, intramuscular administration, and the like can be appropriately selected. In addition, an adjuvant can be used as necessary. After raising the immunized mammal for an appropriate period of time, a small amount of serum from the mammal is sampled from an ear vein or the like, and the antibody titer is measured. When the antibody titer increases, an antigen may be administered as needed for booster immunization. In order to obtain anti-peptide antibodies with a useful titer that can be detected by enzyme-linked immunosorbent assay or the like (for example, ELISA, etc.), it is preferable to administer the antigen at intervals of about two weeks. It is preferable to administer the antigen three or more times. One to two months after the final administration, blood, ascites, etc., preferably blood, of the immunized animal are collected by a known method. The collected blood, etc., can be purified by a known method to improve the antibody titer. Examples of the purification method include centrifugation, precipitation using ammonium sulfate or polyethylene glycol, and chromatography such as ion exchange chromatography, gel filtration chromatography, and affinity chromatography. The antibody of the present invention can be obtained by appropriately selecting or combining these methods.

[0036] A monoclonal antibody can be obtained, for example, by immunizing the aforementioned mammal with a polypeptide containing the amino acid sequence of SEQ ID NO:1 of the present invention, removing, for example, the spleen or lymph nodes, and fusing the antibody-producing cells contained therein with myeloma cells to produce a monoclonal antibody-producing hybridoma. The obtained hybridoma cells are cloned by limiting dilution or the like. The monoclonal antibody can be produced by separating and purifying the collected antibody.

[0037] <Method for detecting intranuclear inclusions of NIID using antibodies> The antibody of the present invention can be used to detect intranuclear inclusions in NIID. The antibody of the present invention specifically binds to a polypeptide containing the amino acid sequence of SEQ ID NO: 1, which is expressed in intranuclear inclusions due to the extension of the GGC repeat sequence, which is the main causative gene of NIID. When the polypeptide is detected in a biological sample from a subject, it is suggested that the subject has an extended GGC repeat sequence, and it can be determined that the subject is highly likely to have NIID. In other words, when the antibody of the present invention is positive, it can be determined that the subject is highly likely to have NIID.

[0038] The detection method of the present invention comprises the following steps. (A) contacting a biological sample with the antibody of the present invention (B) detecting the intranuclear inclusions bound to the antibody by immunohistochemical staining.

[0039] Immunohistochemical staining is a method for visualizing a target protein, etc., by utilizing a specific reaction between an antigen and an antibody. It is characterized by the fact that it can be analyzed while retaining the structural information of a tissue specimen. In the detection method of the present invention, a known immunohistochemical staining method can be used. As long as it includes the above steps (A) and (B), it may also include other steps. For example, before step (A), it may include a step of fixing the biological sample, a deparaffinization step, a hydrophilization step for removing the organic solvent and making it compatible with water, and an antigen activation step for performing a treatment to enhance immune reactivity.

[0040] The fixation method is preferably a method of fixing with formaldehyde / formalin and embedding in paraffin, but methods such as unfixed frozen sections and fixed frozen sections may also be used. The deparaffinization step includes a method of dissolving paraffin embedded in a specimen fixed with a formalin solution or the like attached to a slide glass with an organic solvent. Xylene or toluene is preferable as the organic solvent. The hydrophilization step is preferably performed with a lower alcohol such as methanol or ethanol or acetone. Hydrophilization may be performed by successive washing with a lower alcohol solution with decreasing concentration. Examples of the antigen activation method include a proteolytic enzyme treatment such as pepsin, trypsin, pronase, or protein kinase K; a heat treatment using microwaves, an autoclave, or boiling; and a treatment using an alkali or acid (e.g., hydrochloric acid, formic acid, citric acid). The antigen activation treatment is preferably performed at room temperature for 1 to 30 minutes.

[0041] In addition, since antibodies generally undergo non-specific adsorption reactions with proteins other than the target protein, it is preferable to perform pretreatment using a blocking agent to prevent non-specific adsorption. Examples of blocking agents include normal serum from goats, horses, rabbits, etc., bovine serum albumin, gelatin, proteins derived from living organisms such as skim milk, surfactants, hydroxyalkyl cellulose, polyvinyl alcohol, etc. Two or more of these can also be used in combination. Among these, bovine serum albumin, normal serum, and skim milk are preferred, and bovine serum albumin is more preferred in particular to prevent non-specific adsorption. Pretreatment using a blocking agent is preferably performed at room temperature for 15 to 60 minutes.

[0042] Step (A) is a step of contacting a biological sample with the antibody of the present invention, and any method can be used as long as the antibody of the present invention can be brought into close proximity so that it can bind to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 present in the biological sample. For example, for a solid sample such as skin tissue, a method of applying an antibody-containing solution or immersing a solid sample in an antibody-containing solution can be used, and for a liquid sample such as saliva, a method of mixing the sample with an antibody-containing solution can be used.

[0043] Step (B) is a step of detecting an antibody bound to a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and a reagent for detecting the antibody or a reagent for visualizing the detection reagent may be used. As a reagent for detecting the antibody, a secondary antibody that binds to the antibody of the present invention may be used. The secondary antibody is preferably labeled.

[0044] As a method for visualizing the secondary antibody, it is preferable to use a method in which an enzyme such as peroxidase or alkaline phosphatase is bound to the secondary antibody, or a method in which biotin or the like is added to the secondary antibody, and the secondary antibody is bound to streptavidin or the like to which the enzyme is bound, and a color-developing substrate corresponding to the enzyme is reacted. As a method for binding an enzyme to the secondary antibody, a method (polymer method) in which a reagent in which a large number of the enzyme and the secondary antibody are bound to a dextrin polymer or an amino acid polymer is used can be exemplified. In a method in which a biotinylated secondary antibody and peroxidase-labeled streptavidin are reacted (LSAB method), DAB or the like can be used as a color-developing substrate. In addition, a secondary antibody labeled with a fluorescent dye or the like can also be used. When the sample is treated with a fluorescent-labeled secondary antibody, positive cells are detected using a fluorescent microscope after the treatment. An electrochemiluminescence immunoassay method in which the luminescence intensity due to electric energy is measured, or a radioimmunoassay method in which a label with a radioisotope is used can also be used.

[0045] A measurement method using a fluorescently labeled secondary antibody is preferred because it provides a good balance between ease of operation and sensitivity.

[0046] Specifically, the antibody of the present invention is added to a biological sample as a primary antibody, and after reacting for 15 minutes to 5 hours at 4°C to room temperature, the primary antibody is washed with PBS-T (10 mM phosphate buffer, 0.1% Tween-20), and then a labeled antibody labeled with a fluorescent dye is added as a secondary antibody, and after reacting for 15 minutes to 5 hours at 4°C to room temperature, the secondary antibody is washed with 10 mM PBS. After that, an autofluorescence suppression reagent is added, and the selected secondary antibody is irradiated with an excitation wavelength that causes it to develop color, and the antibody is observed under a fluorescent microscope. In order to increase the detection sensitivity, the ABC method may be used.

[0047] The antibody of the present invention can be used as a diagnostic agent for NIID. The antibody of the present invention may also be used as a kit for diagnosing NIID. The diagnostic kit of the present invention includes the antibody of the present invention and a detection reagent for detecting the antibody. The detection reagent includes, but is not limited to, the above-mentioned reagent for detecting the antibody and a reagent for visualizing the detection reagent. If necessary, other reagents, filter paper, containers, instructions, positive and negative control samples, etc. may be included. EXAMPLES

[0048] The present invention will be specifically described with reference to the following examples, but the present invention is not limited to these.

[0049] <Synthesis of Polypeptides of SEQ ID NOs: 1 to 3> Synthesis of the polypeptides used in the present invention (see Table 1) was commissioned to Cosmo Bio Co., Ltd. The antibody that binds to the polypeptide containing the amino acid sequence of SEQ ID NO:1 was designated S2, the antibody that binds to the polypeptide containing the amino acid sequence of SEQ ID NO:2 was designated S1, and the antibody that binds to the polypeptide containing the amino acid sequence of SEQ ID NO:3 was designated S3. [Table 1]

[0050] <Antibody production> We requested Cosmo Bio Co., Ltd. to create the antibodies. The specific method is as follows. Each synthesized polypeptide was bound to a carrier protein because it was thought that the molecular weight of each polypeptide was small and would not easily cause an immune reaction. First, cysteine ​​was placed at the N-terminus of the synthesized polypeptide, and it was conjugated to a carrier protein using the MBS method. KLH (Keyhole limpet hemocyanin) was used as the carrier protein. This was used as the antigen and one rabbit (Japanese white) was immunized. Four immunizations were performed according to the Day 49 schedule (initial immunization amount: 400 ug / FCA, second and subsequent times: 200 ug / FIA), and whole blood was collected on Day 49. The titer of the rabbit antiserum containing the polyclonal antibody that recognizes the antigen was confirmed by ELISA (6-point measurement). Specific purification was performed using an affinity column bound to a polypeptide containing the amino acid sequence of SEQ ID NO: 1 to 3. Specifically, rabbit antiserum was added to the column and reacted, and then the antibody was eluted using an elution buffer. The eluted fraction was placed in a dialysis membrane and dialyzed overnight, after which the purified antibody was recovered.

[0051] <Immunohistochemical staining> All of the following operations were carried out at room temperature.

[0052] Tissues or cells collected by biopsy were fixed in PBS containing 10% formaldehyde, embedded in paraffin, and sliced ​​into 4 μm-thick sections to prepare pathological specimens. The specimens were deparaffinized by immersing in xylene three times for 5 minutes, and hydrophilized by immersing in 100% ethanol, 95% ethanol, 70% ethanol, and deionized water for 3 minutes each. The pathological specimens were heated in citrate buffer for 15 minutes for antigen activation. After that, in order to prevent nonspecific antibody reactions, the specimens were incubated in 1% bovine serum albumin solution at room temperature for 30 minutes to prepare samples for staining.

[0053] (1) Anti-p62 antibody staining NIID is known to be accompanied by abnormal accumulation and aggregation of p62 protein, and therefore the anti-p62 antibody is positive. Conventional NIID diagnosis has been performed by immunohistochemistry using anti-p62 antibody. However, anti-p62 antibody-positive inclusions have also been confirmed in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, and it is difficult to say that this detection method is specific for NIID. Here, in order to confirm the NIID specificity of the antibody of the present invention, an experiment was performed using the conventional method using anti-p62 antibody.

[0054] Anti-p62 antibody (1:200, Santa Cruz, Sc-28359) was added to the staining sample and reacted for 1 hour. The sample was washed three times for 5 minutes with 10 mM PBS, and reacted for 1 hour with a fluorescent secondary antibody (Thermo Fischer, anti mouse alexa fluor 568) as the secondary antibody. The sample was then washed with 10 mM PBS, treated with an autofluorescence reduction reagent (Vector, Autofluorescence Quenching Kit (SP-8400-15)), and washed with 10 mM PBS. The nuclei were then stained with DAPI staining, which will be described later, and observed under a fluorescent microscope.

[0055] (2) Anti-1C2 antibody staining The anti-1C2 antibody is Monomethyl Histone H3 antibody 1C2 (mouse monoclonal mouse IgG), which stains polyglutamine proteins.

[0056] Anti-1C2 antibody (1:3000, Millipore) was added to the staining sample and reacted for 1 hour. The sample was washed three times for 5 minutes with PBS-T (10 mM phosphate buffer, 0.1% Tween-20, the same applies below), and reacted for 1 hour using a fluorescent secondary antibody (Thermo Fischer, anti mouse alexa fluor 568) as the secondary antibody. After washing with 10 mM PBS, the nuclei were stained with DAPI staining, which will be described later. The sample was treated with the autofluorescence reducing reagent, washed with 10 mM PBS, and observed under a fluorescent microscope.

[0057] (3) S1~S3 antibody staining The staining sample was reacted with S1 to S3 antibodies (100-fold dilution) for 1 hour. It was washed three times for 5 minutes with PBS-T, and reacted with an anti-rabbit fluorescent secondary antibody (Thermo Fischer, anti mouse alexa fluor 488) as the secondary antibody for 1 hour. It was then washed with 10 mM PBS, treated with the autofluorescence reducing reagent, and washed with 10 mM PBS. Then, the nuclei were stained with DAPI staining described later and observed under a fluorescent microscope.

[0058] (4) DAPI staining The cell nucleus staining dye DAPI (Dojindo) was added to the samples stained with various antibodies, and the samples were allowed to soak for 5 minutes, after which they were washed with 10 mM PBS. The samples were mounted using a mounting medium containing a fluorescent anti-fading agent, and the mounted samples were placed on a slide glass, then a cover glass was placed over the sample, and after leaving it for 5 minutes, the cover glass was pressed vertically from above and the periphery was sealed with nail polish. The samples were then observed under a fluorescent microscope.

[0059] <Fluorescence microscope> A confocal laser scanning microscope, FV3000 (OLYMPUS), was used for the microscopic observation. The eyepiece was 10x and the objective lens was 100x (excitation wavelengths: 405nm, 488nm, 561nm).

[0060] <NIID specificity of the antibody of the present invention> The specificity of the antibody of the present invention was examined using dorsal root nerve plasma cells of a patient with NIID. First, in Figures 3(a), 4(a), and 5(a), cell nuclei stained by DAPI staining can be confirmed. In Figures 3(b), 4(b), and 5(b), it can be confirmed that the area where intranuclear inclusions are observed is stained by anti-p62 antibody staining, which has been used conventionally for NIID diagnosis. Figure 3(c) shows the reaction with S1 antibody, Figure 4(c) shows the reaction with S2 antibody, and Figure 5(c) shows the reaction with S3 antibody as the primary antibody, but staining was confirmed only when S2 antibody was used in Figure 4(c), and the stained position was the same as the position where anti-p62 antibody positivity was confirmed (see Figure 4(e)). This revealed that the S2 antibody can specifically detect intranuclear inclusions in NIID, and it was found that the antibody of the present invention can be used for the diagnosis of NIID.

[0061] Furthermore, Figure 10 shows that the antibody of the present invention can be used to diagnose NIID even if the cells to be collected are changed. Figure 10 shows the results of staining using skin fibroblasts from an NIID patient. Skin fibroblasts are easy to obtain because only a small amount of skin, such as skin behind the ear, needs to be collected. In Figures 10(b) and (c), S2 antibody positivity was confirmed at the same position as the anti-p62 antibody positivity position (see Figure 10(e)).

[0062] Like NIID, intranuclear inclusions are observed, but other neurological diseases with different causative genes and symptoms include dentatorubral-pallidoluysian atrophy (sometimes called "DRPLA") and spinocerebellar degeneration (sometimes called "SCA3"), whose main symptom is parkinsonism. DRPLA is a type of spinocerebellar degeneration, and the ATN1 gene is thought to be the causative gene. The CAG repeat sequence of this gene is abnormally extended to 2 to 3 times the normal length, which is thought to result in the production of polyglutamine, and intranuclear inclusions that are positive for immunohistochemistry with anti-1C2 antibody are observed.

[0063] The ATXN3 gene is believed to be the causative gene for SCA3, and it is believed that polyglutamine is generated due to the abnormal expansion of the CAG repeat sequence of this gene to 2-3 times the normal length. This also shows intranuclear inclusions that are positive for anti-1C2 antibody immunostaining.

[0064] The specificity of the antibody of the present invention was confirmed using pontine nucleus neurons of a DRPLA patient in Fig. 6 and pontine nucleus neurons of an SCA3 patient in Fig. 7. In Fig. 6(a) and Fig. 7(a), cell nuclei stained by DAPI staining can be confirmed. In Fig. 6(b) and Fig. 7(b), it can be confirmed that the area where intranuclear inclusions were observed by the conventional anti-1C2 antibody staining is stained. On the other hand, no staining was observed when reacting with S2 antibody (see Fig. 6(c) and Fig. 7(c)). This confirmed that S2 antibody reacts specifically with NIID.

[0065] Fragile X-associated tremor / ataxia syndrome (also called "FXTAS"), which presents a pathological picture similar to that of NIID, has been reported. FXTAS is believed to be caused by abnormal expansion of the GGC repeat sequence in the 5' untranslated region of FMR1. As with NIID, it is currently difficult to distinguish between the two based on pathological findings alone, and genetic testing is required. Figure 8 shows the staining results using skin fibroblasts from an FXTAS patient. In Figure 8(a), cell nuclei stained with DAPI staining can be seen. FXTAS also shows accumulation of p62 protein in the nucleus, and it can be seen in Figure 8(b) that the anti-p62 antibody is positive. On the other hand, in FXTAS, even when the S2 antibody was reacted, the same position as the anti-p62 antibody positive position was not stained (see Figure 8(c)). In addition, since it is known that FXTAS accumulates polyglycine in the nucleus, when stained with anti-polyglycine antibody, the result was positive at the same position as the anti-polyglycine antibody positive position (Figure 9(c)). This shows that it is possible to easily distinguish between FXTAS and NIID, which are said to be difficult to distinguish. [Industrial Applicability]

[0066] The detection antibody of the present invention and the detection method using the same can detect intranuclear inclusions in NIID with high accuracy and ease, and can be used for diagnosing NIID.

Claims

1. An antibody that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:

1.

2. A method for detecting intranuclear inclusions in neuronal intranuclear inclusion disease, comprising the steps of: (A) contacting a biological sample with the antibody of claim 1. (B) detecting the intranuclear inclusions bound to the antibody by immunohistochemical staining.

3. A diagnostic agent for neuronal intranuclear inclusion disease comprising the antibody according to claim 1.

4. A kit for diagnosing neuronal intranuclear inclusions, comprising the antibody according to claim 1 and a detection reagent for detecting said antibody.

Citation Information

Patent Citations

  • Method of detecting neuronal intranuclear inclusion disease patient

    JP2021108552A

Cited By

  • Antibody aiming at neuron intracellular inclusion body disease pathogenic protein PolyGN2C-iso2 as well as preparation method and application thereof

    CN121991223A